NOVO NORDISK A/S
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
STAT3 TARGETING OLIGONUCLEOTIDES AND USES THEREOF
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global GLP-1 Receptor Agonist Market size & share revenue was valued at approximately USD 28.7 Billion in 2025 and is expected to reach USD 34.2 Billion in 2026 and is expected to reach around USD 95.3 Billion by 2035, at a CAGR of 12.1% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Novo Nordisk A/S, Eli Lill
Novo Nordisk A/S (NOVO:CA) Discusses Obesity and Diabetes Portfolio Progress and Pill Launch Milestones at R&D Event Transcript
Novo Nordisk A/S (NOVO:CA) Discusses Obesity and Diabetes Portfolio Progress and Pill Launch Milestones at R&D Event June 7, 2026 7:30 PM EDTCompany...
Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026 Featuring Major Players Novo Nordisk A/S, Eli Lilly and Company, and Pfizer - Global Forecast to 2030 and 2035
The GLP-1 agonists weight loss drugs market offers growth potential through rising obesity rates, innovative drug approvals, and increased insurance coverage. Opportunities include expanding obesity clinics, leveraging GLP-1 therapies beyond diabetes, and addressing production cost challenges due to tariffs. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Dublin, May 21, 2026 (GLOBE NEWSWIRE) -- The "Glucagon-Like Pe
Novo Nordisk’s Weight-Loss Pill Momentum Faces Pricing Pressure
Novo Nordisk A/S (NYSE:NVO) is experiencing strong early uptake for its new weight-loss pill, but intensifying competition with U. S.
Key People
No individuals linked to this entity yet.
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro